The Efficacy of NeuroAid™ (MLC601) in Modulating NF-κB Expression and Improving Outcomes in Traumatic Brain Injury: A Preclinical Study
DOI:
https://doi.org/10.37275/bsm.v9i6.1309Keywords:
MLC601, NeuroAid, NF-κB, Preclinical study, Traumatic brain injuryAbstract
Background: Traumatic brain injury (TBI) represents a significant global health concern, leading to substantial mortality and long-term disability. The intricate pathophysiology of TBI involves primary mechanical damage followed by a cascade of secondary injury events, including neuroinflammation, apoptosis, and oxidative stress. The nuclear factor kappa B (NF-κB) signaling pathway plays a pivotal role in orchestrating the inflammatory response post-TBI and has emerged as a potential therapeutic target. This preclinical study aimed to investigate the efficacy of NeuroAid™ (MLC601), a traditional herbal medicine, in modulating NF-κB expression and improving outcomes in a rat model of TBI.
Methods: This study employed a true experimental in vivo design with a post-test only control group. Male Wistar rats (n=18) were randomly divided into two groups: a control group (n=9) subjected to TBI via a weight-drop method, and an experimental group (n=9) subjected to the same TBI procedure followed by intraperitoneal administration of NeuroAid™ (MLC601) at a dose of 2.5 mg/kg body weight at 5 minutes, 8 hours, and 16 hours post-injury. NF-κB expression in brain tissue samples collected 1 hour after the final dose was assessed using immunohistochemistry and quantified by an immunoreactivity score considering both the intensity and percentage of NF-κB expression.
Results: Immunohistochemical analysis revealed the presence of NF-κB expression in both the nucleus and cytoplasm of neurons in both the control and experimental groups. While the experimental group treated with NeuroAid™ (MLC601) exhibited a lower average immunoreactivity score (0.93) compared to the control group (1.29), the difference in NF-κB expression between the two groups was not statistically significant (p = 0.122).
Conclusion: In this preclinical study using a Wistar rat model of TBI, the administration of NeuroAid™ (MLC601) did not result in a statistically significant reduction in NF-κB expression compared to the untreated control group. Although a trend towards lower NF-κB expression was observed in the NeuroAid™-treated group, further research with larger sample sizes, different dosages, and extended treatment durations is warranted to fully elucidate the potential therapeutic effects of NeuroAid™ (MLC601) in the management of traumatic brain injury.
Authors
- Dedy Chandra Hariyono1*
- Hanis Setyono2
- Ida Bagus Budhi Surya Adnyana3
- 1Department of Surgery, Faculty of Medicine, Universitas Sebelas Maret/Dr. Moewardi General Hospital, Surakarta, Indonesia
- 2Department of Neurosurgery, Faculty of Medicine, Universitas Sebelas Maret/Dr. Moewardi General Hospital, Surakarta, Indonesia
- 3Department of Digestive Surgery, Faculty of Medicine, Universitas Sebelas Maret/Dr. Moewardi General Hospital, Surakarta, Indonesia
Corresponding author Dedy Chandra Hariyono — dedychandramd@gmail.com
Article history
- Submitted
- Accepted
- Published
Downloads
Published
Issue
Section
License
Copyright and licensing
Copyright in each article remains with the author(s). Authors grant Bioscientia Medicina: Journal of Biomedicine and Translational Research a non-exclusive right of first publication and the right to identify itself as the original publisher. No exclusive transfer of copyright is required.
All articles are published under the Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License (CC BY-NC-SA 4.0): https://creativecommons.org/licenses/by-nc-sa/4.0/. Users may copy, redistribute, remix, transform, and build upon the material for non-commercial purposes, provided appropriate attribution is given, a link to the license is supplied, changes are indicated, and adaptations are distributed under the same license.
The license applies to the article's scholarly content unless a credit line states otherwise. Third-party material may be subject to separate rights. Authors retain patent, trademark, moral, and research-data rights. The copyright year follows the article's publication date.
